Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Pneumonia killing more over-65s than Covid but NHS not offering new vaccine despite efficacy warning
Health chiefs have failed to purchase new pneumonia vaccines (file photo) despite warnings that the NHS jab currently offered to over-65s is less effective, The Mail on Sunday has learned. (Source: the Mail online | Health)
Source: the Mail online | Health - January 21, 2023 Category: Consumer Health News Source Type: news

2022 human monkeypox outbreak: Clinical review and management guidance
Conclusion There are no FDA-approved treatments for monkeypox infection. Surveillance and detection of monkeypox among high-risk populations should be implemented to help understand the epidemiology of this disease. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2023 Category: Consumer Health News Source Type: news

Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine
This document contains 4 graphs showing cumulative weekly reports of invasive pneumococcal disease () caused by serotypes not in . Data covers these age groups: under 2s age 2 to 4 years age 5 to 64 years age 65 years or over Data is: from June 2006 to now by epidemiological year from England (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2023 Category: Consumer Health News Source Type: news

​​​​The Upcoming Lunar New Year Holiday Threatens a Grim COVID Toll in China
Harry Li is conflicted. Ideally, the law student wants to spend the Lunar New Year holiday in his home village in northern China’s Hebei province, but he is afraid of spending more than 12 hours on crowded trains and buses lest he brings COVID-19 to his elderly parents, who have not been vaccinated. “It’s been three years since I’ve been home [for Lunar New Year],” says Li, 20, who studies some 700 miles from home in Shanghai. “I was vaccinated nine months ago but everyone around me is still getting sick.” This week, millions of Chinese face a similar conundrum. Before the pandemic...
Source: TIME: Health - January 17, 2023 Category: Consumer Health News Authors: Charlie Campbell / Singapore Tags: Uncategorized China COVID-19 overnight Source Type: news

China: From Zero-Covid to Zero-Control
Medical equipment supplied by the World Food Programme (WFP) arrives in Beijing. Meanwhile, as COVID-19 infections surged in China, coronavirus experts gathered at the UN health agency in Geneva on January 3, to discuss next steps. Photo courtesy of Yingshi ZhangBy Jan ServaesBRUSSELS, Jan 4 2023 (IPS) Three years after the coronavirus first emerged in the Chinese city of Wuhan, the Chinese government began in December to abruptly scrap its harsh containment policy known as “zero-Covid.” This zero-Covid policy relied on strict lockdowns, use of a Covid tracking app, domestic travel restrictions, and quarantin...
Source: IPS Inter Press Service - Health - January 4, 2023 Category: International Medicine & Public Health Authors: Jan Servaes Tags: Asia-Pacific COVID-19 Development & Aid Featured Headlines Health Humanitarian Emergencies TerraViva United Nations IPS UN Bureau Source Type: news

Nurse-Driven Protocol Ups Pneumococcal Vaccination Rates
FRIDAY, Dec. 30, 2022 -- A nurse-driven protocol for improving pneumococcal vaccination rates in immunosuppressed patients is associated with significant increases in vaccination rates, according to a study published online Dec. 1 in The Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2022 Category: Pharmaceuticals Source Type: news

As COVID-19 Cases Surge, China Races To Vaccinate a Reluctant Elderly Population
BEIJING (AP) — Chinese authorities are going door to door and paying people older than 60 to get vaccinated against COVID-19. But even as cases surge, 64-year-old Li Liansheng said his friends are alarmed by stories of fevers, blood clots and other side effects. “When people hear about such incidents, they may not be willing to take the vaccines,” said Li, who had been vaccinated before he caught COVID-19. A few days after his 10-day bout with the virus, Li is nursing a sore throat and cough. He said it was like a “normal cold” with a mild fever. [time-brightcove not-tgx=”true”] Ch...
Source: TIME: Health - December 26, 2022 Category: Consumer Health News Authors: JOE McDONALD / Associated Press Tags: Uncategorized COVID-19 wire Source Type: news

China ’s Stunning U-Turn on Zero-COVID Takes Xi Jinping From Suffocating Control to Callous Inaction
Even for China, where the distance between official narrative and empirical evidence is often a chasm, the last few days have been jarring. On Tuesday, officials announced five deaths from COVID-19—up from two the previous day, which were the first recorded in the country since Dec. 3. On Wednesday, there were officially none. But a glance online tells a different story. Dozens of hearses line up at a Beijing crematorium; bodies wrapped in orange plastic pile in hospitals; patients on ventilators are crammed on a ward floor. [time-brightcove not-tgx=”true”] The decision by Chinese Communist Party (CCP) le...
Source: TIME: Health - December 21, 2022 Category: Consumer Health News Authors: Charlie Campbell / Singapore Tags: Uncategorized China Londontime overnight Source Type: news

Does the keto diet cloud brain PET imaging?
Patients on ketogenic diets appear to have circulating metabolites that reduc...Read more on AuntMinnie.comRelated Reading: PET reveals risk of cardiovascular events in pneumonia patient PET links adipose fat to breast cancer relapse F-18 FDG lymph node uptake assessed in vaccinated COVID-19 patients AI increases PET/CT reporting efficiency in lymphoma staging Keto diet improves PET/CT of cardiac sarcoidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 21, 2022 Category: Radiology Source Type: news

PET reveals risk of cardiovascular events in pneumonia patient
FDG-PET/CT scans have shown that vascular inflammation may be a trigger fo...Read more on AuntMinnie.comRelated Reading: PET links adipose fat to breast cancer relapse F-18 FDG lymph node uptake assessed in vaccinated COVID-19 patients AI increases PET/CT reporting efficiency in lymphoma staging PET/CT bests ultrasound for imaging malignant melanoma PET/CT scans predict low thyroid function in radiotherapy patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 19, 2022 Category: Radiology Source Type: news

The Case for Cautious COVID Optimism This Winter
At this time last year and two years ago, daily new infections and covid-related hospitalizations were already accelerating at a fast clip. BQ.1 and BQ.1.1, the latest Omicron subvariants, came to comprise the majority of cases during a relative lull in the pandemic. Combined with a Thanksgiving Holiday that saw the most travelers since the pandemic started, there has been a steady increase in covid metrics. However, there are many reasons to be optimistic. A combination of factors—a high level of population immunity, Omicron family antigenic drift, convergence of mutations that seem to have hit an evolutionary ceili...
Source: TIME: Health - December 13, 2022 Category: Consumer Health News Authors: Michael Daignault and Monica Gandhi Tags: Uncategorized COVID-19 freelance Source Type: news

Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news